- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Interventions
- M7824, Placebo, Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 12
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hypotension on Induction
- Interventions
- CirQPOD, Standard airway management
- Device
- Lead sponsor
- Zoll Medical Corporation
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Etentamig, Pomalidomide, Daratumumab, Dexamethasone, Carfilzomib, Teclistamab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Cerritos, California • Los Angeles, California + 19 more
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel, Nasojejunal (NJ) tube, Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube
- Drug · Device
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 8
- States / cities
- Fountain Valley, California • Boca Raton, Florida • Jacksonville, Florida + 5 more
- Conditions
- SIOD, Cystinosis, FSGS, SLE Nephritis, CKD Stage 4
- Interventions
- Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg, Total Body Irradiation, ATG, Rituximab, Melphalan, CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Kidney Transplant
- Drug · Radiation · Device + 1 more
- Lead sponsor
- Alice Bertaina
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2034
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Healthy Volunteers, Speech
- Interventions
- Altered Auditory Feedback (AAF), Visual-Acoustic Biofeedback
- Behavioral
- Lead sponsor
- New York University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diffuse Large B-Cell Lymphoma, B-cell Non-Hodgkin's Lymphoma
- Interventions
- Debio 1562, Rituximab
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Urbana, Illinois • Minneapolis, Minnesota + 6 more
- Conditions
- Pancreatic Cancer
- Interventions
- Walking Program
- Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- Magrolimab, Nab-Paclitaxel, Paclitaxel, Sacituzumab Govitecan-hziy
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Fresno, California • Fullerton, California + 16 more
- Conditions
- Overweight, Obesity
- Interventions
- Standard Diet, Ketogenic Diet, Placebo, Nicotinamide Riboside
- Other · Dietary Supplement
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- High-grade Glioma, WHO Grade Ⅳ Glioma
- Interventions
- Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103
- Biological
- Lead sponsor
- Tcelltech Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- Open Label Run In Esomeprazole, Double Blind Esomeprazole, Double Blind Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 1 Month to 11 Months
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Park Ridge, Illinois + 11 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- CP-690,550, Methotrexate, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 694 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 59
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Peoria, Arizona + 48 more
- Conditions
- Obesity
- Interventions
- Feeding Study
- Behavioral
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 166 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Ashland, Massachusetts
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- CK0803, Excipient
- Biological · Other
- Lead sponsor
- Cellenkos, Inc.
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Extensive Stage-small Cell Lung Cancer
- Interventions
- Ifinatamab deruxtecan, Atezolizumab, Carboplatin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
- Conditions
- Labor Stage, First, Prolonged Labor
- Interventions
- Circuit of maternal position changes during labor
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Saint Loius, Missouri
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- OC-L/Montanide ISA 51 VG, Ampligen, Prevnar
- Biological
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Epilepsy
- Interventions
- EEG, Eye Tracking, Behavioral task, fMRI
- Device · Diagnostic Test
- Lead sponsor
- Yale University
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 8
- States / cities
- New Haven, Connecticut • Kansas City, Kansas • Boston, Massachusetts + 5 more
- Conditions
- Breast Cancer, Leptomeningeal Disease
- Interventions
- cDC1 Vaccine, Trastuzumab, Nivolumab
- Biological · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Castrate-Resistant Prostate Cancer
- Interventions
- Atezolizumab, Radium-223 Dichloride
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 17
- States / cities
- Duarte, California • San Francisco, California • New Haven, Connecticut + 14 more
- Conditions
- Metastatic Cancer, Renal Cancer
- Interventions
- Atezolizumab, Bevacizumab, Entinostat
- Drug
- Lead sponsor
- Roberto Pili
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Columbus, Ohio • Philadelphia, Pennsylvania
- Conditions
- Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Bladder Cancer
- Interventions
- Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Glioblastoma, GBM, Glioma
- Interventions
- Trans Sodium Crocetinate (TSC)
- Drug
- Lead sponsor
- Diffusion Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 13 more